How to buy Biofrontera stock

Biofrontera AG is a pharmaceuticals business based in the US. Biofrontera shares (BFRA) are listed on the NASDAQ and all prices are listed in US Dollars. Biofrontera employs 149 staff and has a trailing 12-month revenue of around 0.00.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Biofrontera stock price (NASDAQ: BFRA)

Use our graph to track the performance of BFRA stocks over time.

Biofrontera shares at a glance

• Key figures

Information last updated 2022-05-07.

Latest market close	$1.94
52-week range	$1.50 - $6.89
50-day moving average more info button	$2.89
200-day moving average more info button	$4.65
Wall St. target price	$8.50
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-0.61

Buy Biofrontera shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Biofrontera stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biofrontera price performance over time

Historical closes compared with the close of $1.94 from 2022-05-06

1 week (2022-06-25)	N/A
1 month (2022-06-02)	N/A
3 months (2022-04-06)	-15.65%
6 months (2022-01-06)	-36.81%

1 year (2021-07-06)	-69.69%
2 years (2020-07-06)	-70.87%
3 years (2019-07-03)	18.22
5 years (2017-07-02)	N/A

Is Biofrontera stock undervalued or overvalued?

Valuing Biofrontera stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biofrontera's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biofrontera's EBITDA

Biofrontera's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.5 million.

The EBITDA is a measure of a Biofrontera's overall financial performance and is widely used to measure a its profitability.

Biofrontera financials

Revenue TTM	$28 million
Gross profit TTM	$26.8 million
Return on assets TTM	-10.51%
Return on equity TTM	-124.08%
Profit margin	-55.98%
Book value	$0.76
Market capitalisation more info button	$75.7 million

TTM: trailing 12 months

Biofrontera share dividends

We're not expecting Biofrontera to pay a dividend over the next 12 months.

Biofrontera share price volatility

Over the last 12 months, Biofrontera's shares have ranged in value from as little as $1.5 up to $6.89. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biofrontera's is 1.548. This would suggest that Biofrontera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Biofrontera overview

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co.

Frequently asked questions

What percentage of Biofrontera is owned by institutions?
Currently 3.004% of Biofrontera shares are held by institutions. How many people work for Biofrontera?
Latest data suggests 149 work at Biofrontera. When does the fiscal year end for Biofrontera?
Biofrontera's fiscal year ends in December. Where is Biofrontera based?
Biofrontera's address is: Hemmelrather Weg 201, Leverkusen, Germany, 51377 What is Biofrontera's ISIN number?
Biofrontera's international securities identification number is: US09075G1058 What is Biofrontera's CUSIP number?
Biofrontera's Committee on Uniform Securities Identification Procedures number is: 09075G105